Status:
ACTIVE_NOT_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Has completed the treatment period of study MK-7962-024 (LIGHTRAY) (including Visit 11) on study intervention, did not discontinue study intervention, and is able to safely enroll into MK-7962-031 (LIGHTRAY EXTENSION)
- Has not started treatment with commercially available sotatercept
Exclusion
- The main exclusion criteria include but are not limited to the following:
- \- Has current exposure or is planning to begin treatment with an activin signaling inhibitor (other than sotatercept)
Key Trial Info
Start Date :
May 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 16 2028
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06925750
Start Date
May 12 2025
End Date
June 16 2028
Last Update
December 5 2025
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 1930)
Aurora, Colorado, United States, 80045
2
University of Kansas Medical Center ( Site 1928)
Kansas City, Kansas, United States, 66160
3
University of New Mexico Health Sciences Center - Department of Internal Medicine ( Site 1916)
Albuquerque, New Mexico, United States, 87131
4
Centro Medico Capital ( Site 0002)
La Plata, Buenos Aires, Argentina, B1904AAW